Starling Oncology, Inc.
For the period ended Dec 31, 2024. Filed Mar 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 26, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31, 202 and
| THE ONCOLOGY INSTITUTE, INC.CONSOLIDATED BALANCE SHEETS(US Dollars in thousands, except share data) | ||
|---|---|---|
| December 31, 2024 | December 31, 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $49,669 | $33,488 |
| Marketable securities | — | 49,367 |
| Accounts receivable, net | 48,335 | 42,360 |
| Other receivables | 346 | 551 |
| Inventories | 10,039 | 13,678 |
| Prepaid expenses and other current assets | 4,029 | 4,049 |
| Total current assets | 112,418 | 143,493 |
| Property and equipment, net | 11,888 | 10,883 |
| Operating right of use assets | 25,782 | 29,169 |
| Intangible assets, net | 14,810 | 17,904 |
| Goodwill | 7,230 | 7,230 |
| Other assets | 589 | 561 |
| Total assets | $172,717 | $209,240 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $24,324 | $14,429 |
| Current portion of operating lease liabilities | 6,798 | 6,363 |
| Accrued expenses and other current liabilities | 21,093 | 13,996 |
| Total current liabilities | 52,215 | 34,788 |
| Operating lease liabilities | 23,223 | 26,486 |
| Derivative warrant liabilities | 17 | 636 |
| Conversion option derivative liabilities | 385 | 3,082 |
| Long-term debt, net of unamortized debt issuance costs | 93,131 | 86,826 |
| Other non-current liabilities | 125 | 365 |
| Deferred income taxes liability | 32 | 32 |
| Total liabilities | 169,128 | 152,215 |
| Commitments and contingencies (Note 15) | — | — |
| Stockholders’ equity: | ||
| Common Stock, 0.0001 par value, authorized 500,000,000 shares; 77,470,886 shares issued and 75,737,112 shares outstanding at December 31, 2024 and 75,879,025 shares issued and 74,145,251 shares outstanding at December 31, 2023 | 8 | 8 |
| Series A Convertible Preferred Stock, 0.0001 par value, authorized 10,000,000 shares; 165,045 shares issued and outstanding at December 31, 2024 and 2023 | — | — |
| Additional paid-in capital | 215,413 | 204,186 |
| Treasury Stock at cost, 1,733,774 shares at December 31, 2024 and 2023 | (1,019) | (1,019) |
| Accumulated deficit | (210,813) | (146,150) |
| Total stockholders’ equity | 3,589 | 57,025 |
| Total liabilities and stockholders’ equity | $172,717 | $209,240 |
Note: The Company’s consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities (“VIEs”). The consolidated balance sheets include total assets that can be used only to settle obligations of the Company’s consolidated VIEs totaling $70,804 and $71,305 as of December 31, 2024 and 2023, respectively, and total liabilities of the
Company’s consolidated VIEs for which creditors do not have recourse to the general credit of the Company totaling $274,001 and $210,422 as of December 31, 2024 and 2023, respectively. See Note 17 for further details.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.